Company: INMB
Filing Date: 2025-06-30
Form Type: 8-K
Source: 0001213900-25-059690
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into
a Material Definitive Agreement.

On June 27, 2025, INmune
Bio, Inc. (the “ Company”) entered into a Securities Purchase Agreement (the “ Purchase Agreement”) with two healthcare-focused
institutional investors for the sale of an aggregate of 3,000,000 shares of common stock, par value $0.001 per share (the “ Shares”),
in a registered direct offering (the “ Offering”) at a purchase price of $6.30 per share, priced at-the-market under Nasdaq
rules, for aggregate gross proceeds to the Company of approximately $18.9 million, before deducting placement agent fees and expenses.

The Shares were offered
and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-279036), declared effective by the U. S.
Securities and Exchange Commission (the “ SEC”) on August 7, 2024, and a prospectus supplement filed with the SEC on June 30,
2025. The Offering closed on June 30, 2025.

A. G. P./Alliance Global
Partners acted as the sole placement agent for the Offering pursuant to a Placement Agency Agreement dated June 27, 2025 (the “ Placement
Agency Agreement”). The Company agreed to pay the placement agent a cash fee equal to 7.0% of the gross proceeds and to reimburse
certain legal and other expenses.

Sichenzia Ross Reference Carmel LLP, counsel to the Company, has issued an opinion to the Company regarding the validity of the securities
to be issued in the Offering. A copy of the opinion is filed as Exhibit 5.1 to this Current Report on Form 8-K.

The foregoing summaries
of the Purchase Agreement and the Placement Agency Agreement do not purport to be complete and are qualified in their entirety by reference
to the full text of such agreements, which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated
herein by reference.

Item 8.01. Other Events.